“…15 Keshavan et al provide a perspective on the development of gene therapy for primary mitochondrial diseases. 16 Ng et al show the epic journey to develop gene therapy approaches for inherited neurotransmitter defects culminating with the recent approval of eladocagene exuparvovec (Upstaza™) for aromatic L-amino acid decarboxylase (AADC) deficiency in late 2022. 17 To conclude this special issue, Waddington et al present a magistral review of fetal gene therapy and its complex implications from preclinical evidence to translation, safety and ethics for both the fetus and the mother.…”